中国实用外科杂志2025，Vol.45Issue(6)：630-633,4.DOI:10.19538/j.cjps.issn1005-2208.2025.06.05
胰腺癌治疗的未来——从单一靶点到系统生物学导向联合策略
Future of pancreatic cancer treatment:from single targets to systems biology-driven combination strategies
摘要
Abstract
Pancreatic cancer is characterized by high malignancy and a lack of effective early diagnostic tools,resulting in most patients being diagnosed at an unresectable advanced stage,with a 5-year survival rate of approximately 13％.Traditional gemcitabine-based chemotherapy and single-targeted therapies(e.g.,EGFR inhibitors,KRAS inhibitors)have shown limited efficacy,primarily due to the dense collagenous stroma and cancer-associated fibroblasts forming a drug-resistant barrier,as well as the high degree of tumor heterogeneity.Systems biology enables precise molecular subtyping through the integration of multi-omics data and,when combined with network pharmacology,facilitates the identification of multi-target combination strategies aimed at overcoming drug resistance and the immunosuppressive tumor microenvironment.Digital twin platforms can simulate tumor progression and drug responses in individual patients,thus guiding personalized therapeutic optimization.Clinical trials have demonstrated that KRAS G12D inhibitor MRTX1133,KRAS G12C inhibitors adagrasib and sotorasib,and the PARP inhibitor olaparib exhibit synergistic antitumor activity in specific molecular contexts.Multi-target combination strategies,in conjunction with artificial intelligence and real-time dynamic monitoring,hold promises for improving treatment efficacy and clinical outcomes in pancreatic cancer.关键词
胰腺癌/系统生物学/多靶点治疗Key words
pancreatic cancer/system biology/multi-targeted therapy分类
医药卫生引用本文复制引用
楼文晖..胰腺癌治疗的未来——从单一靶点到系统生物学导向联合策略[J].中国实用外科杂志,2025,45(6):630-633,4.基金项目
Shanghai Municipal Health Commission Clinical Research Project(No.202340104) 上海市卫健委临床研究项目(No.202340104) （No.202340104）
